BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $86.75 Consensus Target Price from Analysts

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) have been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and twenty-three have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $86.75.

A number of equities research analysts have weighed in on BBIO shares. Barclays reiterated an “overweight” rating on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. Wells Fargo & Company increased their price objective on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the company an “outperform” rating in a research report on Thursday, February 12th. Finally, Oppenheimer lowered their target price on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th.

Insider Activity at BridgeBio Pharma

In other news, Director Andrea Ellis sold 64,921 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total value of $4,211,425.27. Following the sale, the director directly owned 18,589 shares in the company, valued at approximately $1,205,868.43. This represents a 77.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total value of $754,600.00. Following the completion of the sale, the director owned 11,589 shares in the company, valued at approximately $874,505.94. This represents a 46.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 237,084 shares of company stock valued at $16,608,419. Corporate insiders own 18.20% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Large investors have recently bought and sold shares of the stock. Strs Ohio lifted its holdings in shares of BridgeBio Pharma by 1.1% during the third quarter. Strs Ohio now owns 18,600 shares of the company’s stock valued at $966,000 after acquiring an additional 200 shares during the period. GAMMA Investing LLC grew its holdings in shares of BridgeBio Pharma by 28.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock worth $53,000 after purchasing an additional 227 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of BridgeBio Pharma by 22.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock worth $54,000 after purchasing an additional 228 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock worth $396,000 after purchasing an additional 244 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its position in shares of BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after purchasing an additional 245 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $73.15 on Wednesday. BridgeBio Pharma has a 12 month low of $28.33 and a 12 month high of $84.94. The company has a market capitalization of $14.18 billion, a P/E ratio of -19.35 and a beta of 1.09. The stock has a 50 day moving average of $71.34 and a two-hundred day moving average of $67.96.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analyst estimates of $150.71 million. The company’s revenue for the quarter was up 2521.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.40) EPS. Sell-side analysts predict that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.